Home Business News New GSK Covid drug approved in UK cuts risk of death by 79% against Omicron variant

New GSK Covid drug approved in UK cuts risk of death by 79% against Omicron variant

by LLB staff reporter
2nd Dec 21 11:36 am

Pharmaceutical giant GlaxoSmithKline (GSK) have had a new Covid drug approved in the UK which works against Omicron and can cut the risk of death by 79%.

the Medicines and Healthcare products Regulatory Agency (MHRA) said, the monoclonal antibody Xevudy (sotrovimab) can cut hospitalisation and death by almost 80% and will be given to people who are at high risk.

MHRA chief executive Dr June Raine said, “I am pleased to say that we now have another safe and effective Covid-19 treatment, Xevudy (sotrovimab), for those at risk of developing severe illness.

“This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to Covid-19, and signals another significant step forward in our fight against this devastating disease.

“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA have conducted a robust and thorough assessment of all the available data.”

GSK and Vir Biotechnology said initial data shows the new Covid drug “retains activity against key mutations of the new Omicron Sars-CoV-2 variant.”

George Scangos, chief executive of Vir, said, “Sotrovimab was deliberately designed with a mutating virus in mind.

“By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current Sars-CoV-2 virus and future variants that we expected would be inevitable.

“This hypothesis has borne out again and again, with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data.

“We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”

Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines, said, “Based on the data reviewed by the Commission and its expert group, it is clear sotrovimab is another safe and effective treatment to help us in our fight against Covid-19.”

The British government has now ordered 100,000 doses of the new Covid drug.

You may also like

Leave a Comment


Sign up to our daily news alerts